EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Phase 1 Completed
11 enrolled
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Phase 1 Completed
25 enrolled
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Phase 1 Completed
21 enrolled
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Phase 1 Completed
41 enrolled
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Phase 1 Completed
18 enrolled 12 charts
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Phase 1 Completed
68 enrolled
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Phase 1 Completed
8 enrolled 9 charts
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Phase 1 Completed
34 enrolled
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
ASCR
Phase 1 Completed
14 enrolled
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
Phase 1 Completed
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Phase 1 Completed
6 enrolled
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Phase 1 Completed
16 enrolled
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
Phase 1 Completed
33 enrolled
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Phase 1 Completed
22 enrolled 16 charts
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Phase 1 Completed
18 enrolled
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
Phase 1 Completed
103 enrolled
An East Asian Study of LDE225
Phase 1 Completed
45 enrolled
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
Phase 1 Completed
57 enrolled
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
Phase 1 Completed
12 enrolled
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Phase 1 Completed
81 enrolled
Aflac ST0901
Phase 1 Completed
18 enrolled
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Phase 1 Completed
21 enrolled
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
Phase 1 Completed
9 enrolled
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Phase 1 Completed
5 enrolled
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
Phase 1 Completed
12 enrolled
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Phase 1 Completed
8 enrolled
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Phase 1 Completed
18 enrolled
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Phase 1 Completed
27 enrolled
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase 1 Completed
55 enrolled
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Completed
22 enrolled
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase 1 Completed
28 enrolled
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Phase 1 Completed
21 enrolled
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
Phase 1 Completed
10 enrolled
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
Phase 1 Completed
26 enrolled
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Phase 1 Completed
16 enrolled
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Phase 1 Completed
31 enrolled
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Completed
60 enrolled
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
Phase 1 Completed
34 enrolled
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase 1 Completed
72 enrolled
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Phase 1 Completed
24 enrolled
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Phase 1 Completed
45 enrolled
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Phase 1 Completed
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
95 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Phase 1 Completed
60 enrolled